Diuretic therapy in heart failure: Current controversies and new approaches for fluid removal

Journal of Cardiovascular Medicine

Volumn 11, Issue 8, 2010, Pages 563-570

  Brandimarte, Filippo ^a   Mureddu, Gian Francesco ^b   Boccanelli, Alessandro ^c   Cacciatore, Giuseppe ^d   Brandimarte, Camillo ^a   Fedele, Francesco ^a   Gheorghiade, Mihai ^e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Echo Lab   (United Kingdom)

^c Department Cardiovascular Diseases ^*  (Australia)

^d Department of Cardiovascular Diseases   (Australia)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

adenosine antagonists; cardiorenal syndrome; congestion; heart failure; loop diuretic; mortality; renal dysfunction; ultrafiltration; vasopressin antagonists

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENONE; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FUROSEMIDE; LOOP DIURETIC AGENT; METOLAZONE; NESIRITIDE; NEUROHORMONE; NON POTASSIUM SPARING DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; ROLOFYLLINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE; UNCLASSIFIED DRUG; ADENOSINE; HORMONE ANTAGONIST; VASOPRESSIN DERIVATIVE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY FAILURE; MORTALITY; REVIEW; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; ULTRAFILTRATION; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DRUG EFFECTS; ELECTROLYTE BALANCE; HEMOFILTRATION; KIDNEY DISEASE; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME;

ADENOSINE; CARDIOVASCULAR DISEASES; HEART FAILURE; HEMOFILTRATION; HORMONE ANTAGONISTS; HUMANS; KIDNEY DISEASES; RISK ASSESSMENT; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VASOPRESSINS; WATER-ELECTROLYTE BALANCE;

EID: 77954393284     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283376bfa     Document Type: Review

References (66)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics\2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119:e21-e181. (Pubitemid 43754289)
2. FangJ,Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008; 52:428-434.
3. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24:442-463. (Pubitemid 36286187)
4. Tavazzi L, Maggioni AP, Lucci D, Cacciatore G, Ansalone G, Oliva F, Porcu M. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 2006; 27:1207-1215. (Pubitemid 43752391)
5. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MG, Abraham WT, et al., for the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149:209-216.
6. Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 2004; 148:43-51. (Pubitemid 38900479)
7. Gheorghiade M, Shin DD, Thomas TO, Brandimarte F, Fonarow GC, Abraham WT. Congestion isanimportant diagnostic and therapeutic target in heart failure. Rev Cardiovasc Med 2006; 7:S12-S24. (Pubitemid 44478683)
8. Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007; 99:4A-23A. (Pubitemid 46099035)
9. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al., American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53:e1-e90.
10. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology
11. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al.; ESC Committee for Practice Guidelines
12. Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388-2442.
13. Cotter G, Weissgarten J, Metzkor E, Moshkovitz Y, Litinski I, Tavori U, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 1997; 62:187-193. (Pubitemid 27373467)
14. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351:389-393. (Pubitemid 28064161)
15. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100:1311-1315. (Pubitemid 29440124)
16. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006; 27:1431-1439. (Pubitemid 43998077)
17. Domanski M, Tian X, Haigney M, Pitt B. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail 2006; 12:327-332. (Pubitemid 43817590)
18. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97:1759-1764. (Pubitemid 43817867)
19. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007; 9:1064-1069. (Pubitemid 47451811)
20. Peacock WF, Costanzo MR, De Marco T, Lopatin M, Wynne J, Mills RM, Emerman CL, ADHERE Scientific Advisory Committee and Investigators. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009; 113:12-19.
21. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, et al. Open label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111:513-520.
22. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4:507-513. (Pubitemid 36564972)
23. Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther 2005; 19:301-306. (Pubitemid 41778811)
24. Ezekowitz JA, Hernandez AF, Starling RC, Yancy CW, Massie B, Hill JA, et al. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). Am Heart J 2009; 157:219-228.
25. Morgan DB, Davidson C. Hypokalemia and diuretics: an analysis of publications. BMJ 1980; 280:905-908.
26. Dargie HJ, Cleland JG, Leckie BJ, Inglis CG, East BW, Ford I. Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation 1987; 75:IV98-IV107.
27. Hropot M, Fowler N, Karlmark B, Giebisch G. Tubular action of diuretics: distal effects on electrolyte transport and acidification. Kidney Int 1985; 28:477-489. (Pubitemid 15248037)
28. Bhatia ML, Singh I, Manchanda SC, Khanna PK, Roy SB. Effect of furosemide on pulmonary blood volume. BMJ 1969; 2:551-552.
29. Dikshit K, Vyden JK, Forrester JS, Chaterjee K, Prakash P, Swan HJC. Renal and extrarenalhaemodynamic effectsoffurosemideincongestive heartfailure after acute myocardial infarction. N Engl J Med 1973; 288:1087-1090.
30. Beohar N, Erdogan AK, Lee DC, Sabbah HN, Kern MJ, Teerlink J, et al. Acute heart failure syndromes and coronary perfusion. J Am Coll Cardiol 2008; 52:13-16. (Pubitemid 351852938)
31. McCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004; 44:1301-1307. (Pubitemid 39208889)
32. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43:2028-2035. (Pubitemid 38686797)
33. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717. (Pubitemid 29407370)
34. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al., Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
35. Brandimarte F, Blair JE, Manuchehry A, Fedele F, Gheorghiade M. Aldosterone receptor blockade in patients with left ventricular systolic dysfunction following acute myocardial infarction. Cardiol Clin 2008; 26:91-105. (Pubitemid 351291689)
36. Boccanelli A, Mureddu GF, Cacciatore G, Latini R, Masson S, Porcu M, et al. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure (AREA IN CHF): final results. Eur J Heart Failure 2009; 11:68-76.
37. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57:17-22. (Pubitemid 17216948)
38. Knight RK, Miall PA, Hawkins LA, Dacombe J, Edwards CR, Hamer J. Relation of plasma aldosterone concentration to diuretic treatment in patients with severe heart disease. Br Heart J 1979; 42:316-325.
39. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
40. Francis GS, Siegel RM, Goldsmith SR. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med 1985; 103:1-6.
41. Martin SJ, Danziger LH. Continuous infusion of loop diuretics in the critically ill: a review of the literature. Crit Care Med 1994; 22:1323-1329. (Pubitemid 24244840)
42. Gulbis BE, Spencer AP. Efcacy and safety of a furosemide continuous infusion following cardiac surgery. Ann Pharmacother 2006; 40:1797-1803.
43. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28:376-382. (Pubitemid 26274331)
44. Howard PA, Dunn MI. Aggressive diuresis for severe heart failure in the elderly. Chest 2001; 119:807-810. (Pubitemid 32197652)
45. Cioffi G, Tarantini L, Pulignano G, Del Sindaco D, De Feo S, Opasich C, et al. Prevalence, predictors and prognostic value of acute impairment in renal function during intensive unloading therapy in a community population hospitalized for decompensated heart failure. J Cardiovasc Med 2007; 8:419-427. (Pubitemid 46766538)
46. Howard PA, Dunn MI. Effectiveness of continuous infusions of loop diuretics for severe heart failure. J Cardiovasc Med 2006; 7:5-10.
47. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005; 3:CD003178.
48. Reddy P, Mooradian AD. Diuretics: an update on the pharmacology and clinical uses. Am J Ther 2009; 16:74-85.
49. Gheorghiade M, Pang P. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53:557-573.
50. Gottlieb SS, Abraham W,Butler J,Forman DE, Loh E, MassieBM,et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002; 8:136-141. (Pubitemid 34857278)
51. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003; 9:13-25. (Pubitemid 36356697)
52. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147:331-338. (Pubitemid 38176835)
53. Schrier RW. Role of diminished renal function in cardiovascular mortality. J Am Coll Cardiol 2006; 47:1-8.
54. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681-689. (Pubitemid 30167025)
55. Mahon NG, Blackstone EH, Francis GS, Starling RC III, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 40:1106-1113.
56. Paterna S, Fasullo S, Di Pasquale P. High-dose torasemide is equivalent to high-dose furosemide with hypertonic saline in the treatment of refractory congestive heart failure. Clin Drug Investig 2005; 25:165-173. (Pubitemid 40460642)
57. Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 2003; 145:459-466. (Pubitemid 36390492)
58. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46:1785-1791. (Pubitemid 41579797)
59. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al., Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297:1332-1343.
60. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al., Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297:1319-1331. (Pubitemid 46513233)
61. Goldsmith SR, Elkayam U, Haught WH, Barve A, He W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008; 14:641-647.
62. Dohadwala MM, Givertz MM. Role of adenosine antagonism in the cardiorenal syndrome. Cardiovasc Ther 2008; 26:276-286.
63. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM, Protect Steering Committee, Investigators, and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008; 14:631-640.
64. Costanzo MR. Ultrafiltration in the management of heart failure. Curr Opin Crit Care 2008; 14:524-530.
65. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al., UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49:675-683. (Pubitemid 46205043)
66. Kazory A, Ross EA. Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation 2008; 117:975-983. (Pubitemid 351272594)